公开(公告)号：US20230313189A1

公开(公告)日：2023-10-05

申请号：US18054116

申请日：2022-11-09

Applicant: Genentech, Inc.

Inventor： Alexander MUNK ,  Helene M. GYLLING ,  Jesse Eric HANSON ,  Lukasz J. KIELPINSKI

IPC: C12N15/113 ,  C12Q1/6883

CPC classification number: C12N15/113 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/315 ,  C12N2310/341 ,  C12N2310/3341

Abstract: The present invention relates to complement component 4 (C4) inhibitors for use in treatment of a neurological disease. The invention in particular relates to the use of C4 inhibitors for down-regulation of C4 expression. The invention also relates to nucleic acid molecules, which are complementary to C4A and/or C4B and capable of reducing the level of an C4A and/or C4B mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a neurological disease.

公开(公告)号：US20230399643A1

公开(公告)日：2023-12-14

申请号：US18054115

申请日：2022-11-09

Applicant: Genentech, Inc.

Inventor： Alexander MUNK ,  Helene M. GYLLING ,  Jesse Eric HANSON ,  Lukasz J. KIELPINSKI

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/32 ,  C12N2310/315

Abstract: The present invention relates to complement component 1s (C1S) inhibitors for use in treatment of neurological diseases. The invention in particular relates to the use of C1S inhibitors for down-regulation of C1S expression. The invention also relates to nucleic acid molecules, which are complementary to C1S and capable of reducing the level of an C1S mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of neurological diseases.

公开(公告)号：US20230323362A1

公开(公告)日：2023-10-12

申请号：US18054113

申请日：2022-11-09

Applicant: Genentech, Inc.

Inventor： Alexander MUNK ,  Helene M. GYLLING ,  Jesse Eric HANSON ,  Lukasz J. KIELPINSKI

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12Y304/21041 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/3341 ,  C12N2310/346 ,  C12N2310/14

Abstract: The present invention relates to complement C1r subcomponent (C1R) inhibitors for use in treatment of neurological diseases. The invention in particular relates to the use of C1R inhibitors for down-regulation of C1R expression. The invention also relates to nucleic acid molecules, which are complementary to C1R and capable of reducing the level of an C1R mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of neurological diseases.